- 收听数
- 0
- 听众数
- 8
- 最后登录
- 2025-1-7
- QQ
 - UID
- 9301
- 阅读权限
- 10
- 帖子
- 1191
- 精华
- 0
- 在线时间
- 380 小时
- 注册时间
- 2014-5-1

- 科研币
- 2
- 速递币
- 25
- 娱乐币
- 1820
- 文献值
- 0
- 资源值
- 0
- 贡献值
- 0
|
5速递币
题名 | Final overall survival results from a randomised, Phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). | 链接 | http://annonc.oxfordjournals.org/content/early/2015/07/03/annonc.mdv276.full.pdf+html |
|
|